Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Share :
Published: 5 Jun 2022
Views: 83
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Dr Takayuki Yoshino presents his study into trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer.

He discusses the methodology for his data analysis study where the team searched multiple databases; only randomised controlled trials (RCTs), non-RCTs, and prospective observational studies of previously treated patients with mCRC were evaluated.

Dr Yoshino summarises the outcome of the meta-analysis study which suggested that FTD/TPI + BEV provides benefits over FTD/TPI in patients with refractory mCRC and has a similar safety profile, but it is associated with a higher rate of grade ≥3 neutropenia.

Watch our interview with Dr Yoshino here

Watch Dr Eng comment on the study here

Watch Dr Cremolini comment on the study here

Read the news story on the study here